A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus

Esophageal adenocarcinoma risk in Barrett’s esophagus (BE) is increased 30- to 125-fold versus the general population. Among all BE patients, however, neoplastic progression occurs only once per 200 patient-years. Molecular biomarkers are therefore needed to risk-stratify patients for more efficient...

Full description

Saved in:
Bibliographic Details
Main Authors: Jin, Zhe, Cheng, Yulan, Gu, Wen, Zheng, Yingye, Sato, Fumiaki, Mori, Yuriko, Olaru, Alexandru V., Paun, Bogdan C., Yang, Jian, Kan, Takatsugu, Ito, Tetsuo, Hamilton, James P., Selaru, Florin M., Agarwal, Rachana, David, Stefan, Abraham, John M., Wolfsen, Herbert C., Wallace, Michael B., Shaheen, Nicholas J., Washington, Kay, Wang, Jean, Canto, Marcia Irene, Bhattacharyya, Achyut, Nelson, Mark A., Wagner, Paul D., Romero, Yvonne, Wang, Kenneth K., Feng, Ziding, Sampliner, Richard E., Meltzer, Stephen J.
Format: Artigo
Language:Inglês
Published: 2009
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2752375/
https://ncbi.nlm.nih.gov/pubmed/19435894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-0028
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items